China-based Innovent Biologics, Inc. (Innovent), a world-class China-based biopharmaceutical company that develops high quality drugs, announced yesterday that its IND application for IBI-188, a fully human anti-CD47 monoclonal antibody (mAb) drug candidate, has been approved by the US Food & Drug Administration (FDA) to initiate clinical trials for patients with advanced malignancies and lymphomas.
Innovent Biologics was formed in 2011 and has raised private venture from 16 different venture capitalists/private equity groups. They are in the process of filing an IPO. See more information via Owler.
Source: PR Newswire
